Gene targeting techniques for Huntington's disease

被引：18

作者：

Fields, Eric ^{[1
]}

Vaughan, Erik ^{[1
]}

Tripu, Deepika ^{[1
]}

Lim, Isabelle ^{[1
]}

Shrout, Katherine ^{[1
]}

Conway, Jessica ^{[1
]}

Salib, Nicole ^{[1
]}

Lee, Yubin ^{[1
]}

Dhamsania, Akash ^{[1
]}

Jacobsen, Michael ^{[1
]}

Woo, Ashley ^{[1
]}

Xue, Huijing ^{[2
]}

Cao, Kan ^{[1
,2
]}

机构：

[1] Univ Maryland, Gemstone Honors Program, College Pk, MD 20742 USA

[2] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA

来源：

AGEING RESEARCH REVIEWS | 2021年 / 70卷

关键词：

Huntington's disease; Allele-specific targeting; Prime editing; SNPs; MUTANT HUNTINGTIN; CAG REPEAT; GUT MICROBIOTA; MOUSE MODEL; RNA; MECHANISMS; THERAPY; PHOSPHORYLATION; INACTIVATION; CILIOGENESIS;

D O I：

10.1016/j.arr.2021.101385

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in the HTT gene. Wild-type huntingtin protein (HTT) is essential, involved in a variety of crucial cellular functions such as vesicle transportation, cell division, transcription regulation, autophagy, and tissue maintenance. The mutant HTT (mHTT) proteins in the body interfere with HTT's normal cellular functions and cause additional detrimental effects. In this review, we discuss multiple approaches targeting DNA and RNA to reduce mHTT expression. These approaches are categorized into non-allele-specific silencing and allele-specificsilencing using Single Nucleotide Polymorphisms (SNPs) and haplogroup analysis. Additionally, this review discusses a potential application of recent CRISPR prime editing technology in targeting HD.

引用

页数：8

共 50 条

[1] Therapeutic strategies for Huntington's disease
Estevez-Fraga, Carlos
Flower, Michael D.
Tabrizi, Sarah J.
CURRENT OPINION IN NEUROLOGY, 2020, 33 (04) : 508 - 518
[2] Targeting Histone Deacetylases for the Treatment of Huntington's Disease
Gray, Steven G.
CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (06) : 348 - 361
[3] The potential of gene editing for Huntington's disease
Duan, Wenzhen
Urani, Ece
Mattson, Mark P.
TRENDS IN NEUROSCIENCES, 2023, 46 (05) : 365 - 376
[4] Allele-specific silencing of mutant Huntington's disease gene
Zhang, Yu
Engelman, Joshua
Friedlander, Robert M.
JOURNAL OF NEUROCHEMISTRY, 2009, 108 (01) : 82 - 90
[5] Therapeutic targeting of Huntington's disease: Molecular and clinical approaches
Kumar, Dhiraj
Hasan, Gulam Mustafa
Islam, Asimul
Hassan, Md. Imtaiyaz
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 655 : 18 - 24
[6] Targeting the proteostasis network in Huntington's disease
Soares, Tania R.
Reis, Sara D.
Pinho, Brigida R.
Duchen, Michael R.
Oliveira, Jorge M. A.
AGEING RESEARCH REVIEWS, 2019, 49 : 92 - 103
[7] The Huntington's Disease Gene Discovery
Franklin, Gustavo L.
Teive, Helio A. G.
Tensini, Fernando Spina
Camargo, Carlos Henrique Ferreira
de Lima, Nayra de Souza Carvalho
de dos Santos, Diego de Castro
Meira, Alex T.
Tabrizi, Sarah J.
MOVEMENT DISORDERS, 2024, 39 (02) : 227 - 234
[8] Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA
Shannon, Kathleen M.
CNS DRUGS, 2020, 34 (03) : 219 - 228
[9] Drug targeting of dysregulated transcription in Huntington's disease
Kazantsev, Aleksey G.
Hersch, Steven M.
PROGRESS IN NEUROBIOLOGY, 2007, 83 (04) : 249 - 259
[10] Targeting Huntingtin Expression in Patients with Huntington's Disease
Tabrizi, Sarah J.
Leavitt, Blair R.
Landwehrmeyer, G. Bernhard
Wild, Edward J.
Saft, Carsten
Barker, Roger A.
Blair, Nick F.
Craufurd, David
Priller, Josef
Rickards, Hugh
Rosser, Anne
Kordasiewicz, Holly B.
Czech, Christian
Swayze, Eric E.
Norris, Daniel A.
Baumann, Tiffany
Gerlach, Irene
Schobel, Scott A.
Paz, Erika
Smith, Anne V.
Bennett, C. Frank
Lane, Roger M.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2307 - 2316

← 1 2 3 4 5 →